Last reviewed · How we verify

NCT06367868

Optic Nerve Sheath Diameter: A Non-Invasive Indicator of Intracranial Pressure in the Intensive Care Unit Monitoring

Completed NA Last updated 16 April 2024
What this trial tests

NA trial testing After 5 ml CSF Drainage in ICP (Intracranial Pressure) Increase in 44 participants. Completed in 1 December 2022.

Timeline
9 September 2021
Primary endpoint
1 June 2022
1 December 2022

Quick facts

Lead sponsorIstanbul University - Cerrahpasa
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment44
Start date9 September 2021
Primary completion1 June 2022
Estimated completion1 December 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul University - Cerrahpasa

Who can join

Adults 18 to 80, any sex, with ICP (Intracranial Pressure) Increase or Optic Nerve Sheath Diameter. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determination of high intracranial pressure (ICP) is necessary for the treatment of patients with raised ICP to improve long-term neurological outcomes. Ultrasonographic optic nerve sheath diameter (ONSD) measurement is a noninvasive, easily performed and cost effective technique for detecting high ICP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Istanbul University - Cerrahpasa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06367868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing